

9320898 (8)
PD-ADD-42-81
653

NONCAPITAL PROJECT PAPER (PROP)

Country: Worldwide

Project No. 931-11-570-898

Submission Date: July 21, 1970 Original _____ Revision No. 6P.

Project Title: Grant to New York Academy of Sciences for International Conference on Prostaglandins

U.S. Obligation Span: FY-1971

Physical Implementation Span: Through June 30, 1971

Gross life-of-project financial requirements:

U.S. dollars \$60,000

I. SUMMARY DESCRIPTION

This proposal is for a grant to the New York Academy of Sciences in support of an International Meeting on Prostaglandins to be held in New York at the Barbizon Plaza Hotel beginning September 17 through 19, 1970.

II. SETTING AND ENVIRONMENT

Prostaglandins are naturally occurring derivatives of polyunsaturated fatty acids and have very potent effects on many different organ systems, including the brain, the endocrine and reproductive systems. Recent experiments show promise for the use of certain prostaglandin series of compounds or their analogs as contraceptives and abortifacients. Because of their potential use, A.I.D. is supporting a comprehensive program of prostaglandin research in an effort to develop a more effective safe and acceptable contraceptive suitable to the needs of women in the developing countries.

Two international prostaglandin meetings have been held previously, one at the Karolinska Institute in Sweden in 1966, and the other at the Worcester Foundation in Massachusetts in 1967. This will be the third international meeting, and owing to the recent discovery of the effectiveness of some prostaglandins as abortifacients this third meeting is most timely.

III. STRATEGY

This meeting will concentrate on those aspects of prostaglandins which allow their rapid development and introduction into clinical areas

especially that of fertility control. Represented at this meeting will be all the distinguished workers and pioneers in this field including Professor Von Euler who first discovered prostaglandins. In addition to the participation of approximately 34 of these distinguished professionals from research institutions, medical centers, pharmaceutical firms and universities in the U.S., Canada, Sweden, Holland, Scotland, England and Nigeria; invitations will be issued to approximately twenty additional scientists from other countries including Eastern Europe, Latin America, Near East and South Asia, the Far East and Africa.* Prominent leaders in the U.S. in bio-medicine, obstetrics and gynecology who are concerned about research for improved contraceptives will also be invited. A total of more than 100 professionals are expected to attend this meeting which will provide an excellent vehicle through which to advance research in developed and lesser developed countries, on prostaglandins as contraceptive agents. This meeting should be especially helpful to scientists from the LDC's who will have the opportunity to become acquainted with the leading workers in this field and establish a rapport which could help further prostaglandin research in their countries.

IV. PLANS, TARGET, OUTPUT

The Conference will last three days. The first session will review what is known about the chemistry of the prostaglandins, especially with respect to their chemical synthesis. One complete day will be devoted to this program which will be chaired by Dr. John Pike of the Upjohn Company and also by Dr. David Van Dorp of Unilever Research Laboratories in Holland. The second major area which will be covered by the program deals with the Biosynthesis and Metabolism of prostaglandins. This session will be chaired by Dr. B. Samuelson from Sweden and Dr. J. R. Vane of Royal College of Surgeons in London. Since there is a bewildering variety of actions of prostaglandins two sessions will be devoted to Mechanism of Action. These sessions will be chaired by Drs. Orloff, Horton, Wolfe, and Ramwell from the U.S., Scotland and Canada. Perhaps the most important session of all, will deal with the reproductive aspects of prostaglandins. Scientists who have had intimate experience with the use of prostaglandins as luteolytic substances in animals, primates and in man will conduct and participate in this session. This session will be chaired by Dr. Vande Wiele from Columbia University and S. Bergstrom of the Karolinska Institute in Sweden.))

The proceedings of the Conference will be published in the Annals of the New York Academy of Sciences. The monograph will be comprised of the papers presented at the Conference plus the discussions. Since the most significant part of the meeting will be the discussions, care will be taken to ensure that an adequate and definitive transcription will be available. This monograph which will contain information critical for the

* The scientists from Eastern Europe are important because the large number of pregnancy terminations in those countries and their good medical care system will doubtless be important in early clinical trial of prostaglandins.

development of prostaglandins as contraceptive agents will receive wide distribution. In addition to its membership, the New York Academy of Sciences has a subscription list of over one thousand worldwide libraries, medical schools, and research centers, that take all of their publications. One thousand copies of these proceedings will be furnished without additional charge to A.I.D.

V. BUDGET

The New York Academy of Sciences has not been successful in raising sufficient funds to support this meeting. To date contributions total only several thousand dollars. As a result the Academy has sought assistance from A.I.D. to assure the success of this undertaking in which we share a mutual interest and concern.

The Academy estimates that the cost of the Conference will total approximately \$56,000 as itemized below:

<u>Budgetary Item</u>	<u>Amount</u>
1. Salaries prorated	
a) Administration	\$3,000
b) Editorial	7,000
c) Public Relations	1,800
2. Administrative cost	
a) Office supplies and stationery	200
b) Postage	200
c) Telephone and Telegraph	250
d) Printing and mailing of programs	4,250
3. Transportation: (speakers) Domestic	2,818
and session chairmen) Foreign	6,755
4. Housing and subsistence of) Domestic	1,260
participants) Foreign	1,100
5. Rental of conference space and ancillary charges	1,573
6. Cost of printing the proceedings	24,000
7. Distribution cost and mailing of the conference monograph	1,900
	<hr/>
	\$56,106

One half of this figure represents the cost of printing the proceedings. Administrative and logistical costs are moderately projected. The other major cost item is for the transportation and subsistence of approximately 34 professionals from the U.S. and abroad who preside and present papers at the conference. Not included in the estimated costs are an additional \$20,000 to pay for the subsistence and travel of approximately 20 scientists who will be invited from Eastern Europe, Latin America, the Near East and South Asia, East Asia and Africa. This would bring the total costs of the Conference to approximately \$76,000.

VI. RECOMMENDATION

A major thrust of A.I.D.'s research effort is to develop new contraceptive techniques of greater convenience and acceptability to users in LDC's and adequately safe to allow freedom from need for sterilization. Such techniques will be ideal in all countries and cultures.

Since there is considerable evidence that Prostaglandins could act as effective ~~of~~ contraceptive agents, it is in the interest of A.I.D. to promote as much prostaglandin research and exchange of information as possible among the international scientific community to more rapidly achieve our goals.

Since it is to A.I.D.'s interest that the Conference be held now, we recommend that a grant totalling \$60,000 be made to the New York Academy of Sciences to assist in (1) defraying the costs of items 3 through 7 in their budget, and (2) to pay for the travel of approximately 20 scientists invited from Eastern Europe and the developing countries.

Proj. 9320 898
PH-

PROJECT AUTHORIZATION

1. PROJECT NUMBER 932-11-570-898	3. COUNTRY WORLDWIDE	4. AUTHORIZATION NUMBER TA 0092 Amendment #1
2. PROJECT TITLE NEW YORK ACADEMY OF SCIENCES - THIRD INTERNATIONAL CONFERENCE ON PROSTAGLANDINS		5. AUTHORIZATION DATE September 3, 1970
7. LIFE OF PROJECT		6. PROP DATED July 21, 1970

a. Number of Years of Funding: 1
Starting FY 1971; Terminal FY 1971

b. Estimated Duration of Physical Work
After Last Year of Funding (in Months): None

8. FUNDING BY FISCAL YEAR (in U.S. \$ or \$ equivalent)	DOLLARS (000s)		P.L. 480 CCC + FREIGHT	LOCAL CURRENCY Exchange Rate: \$1 =			
	GRANT	LOAN		U.S. OWNED		HOST COUNTRY	
				GRANT	LOAN	JOINTLY PROGRAMMED	OTHER
Prior through Actual FY							
Operational FY 1971	60						
Budget FY							
B + 1 FY							
B + 2 FY							
B + 3 FY							
All Subsequent FY's							
TOTAL	60						

9. DESCRIBE SPECIAL FUNDING CONDITIONS OR RECOMMENDATIONS FOR IMPLEMENTATION, AND LIST KINDS AND QUANTITIES OF ANY P.L. 480 COMMODITIES. The purpose of this amendment is to clarify the funding authority intended by the original project authorization. Accordingly, Project Authorization TA 0092 is amended by deletion of paragraph 9 and substitution of the following therefor: Items eligible for financing under this authorization are limited to budget items 3 through 7 for the Conference as stated in the body of the PROP, and to \$22,000 to pay for the subsistence and travel of approximately 20 scientists who will be invited from Eastern Europe, LA, NESAs, EA and APR. Funds not utilized must be refunded to

10. CONDITIONS OF APPROVAL OF PROJECT. AID not later than June 30, 1971.


No travel or per diem for employees of the USG or corporations established for profit may be paid from funds authorized under this Grant.

(Use continuation sheet if necessary)

11. Approved in substance for the life of the project as described in the PROP, subject to the conditions cited in Block 10 above, and the availability of funds. Detailed planning with cooperating country and drafting of implementation documents is authorized.

This authorization is contingent upon timely completion of the self-help and other conditions listed in the PROP or attached thereto.

This authorization will be reviewed at such time as the objectives, scope and nature of the project and/or the magnitudes and scheduling of any inputs or outputs deviate so significantly from the project as originally authorized as to warrant submission of a new or revised PROP.

A.I.D. APPROVAL  SIGNATURE AA /TA, Joel Bernstein TITLE	DATE 9/8/70	CLEARANCES	DATE
		TA/PM, John H. Kean <i>JHK</i>	9/3/70
		TA/PM, Kenneth S. Levick <i>KS</i>	9/3/70
		TA/PM, R.T. Ravenholt <i>TR</i>	9/3/70 (draft)
		TA/PM, A.R. Richstein <i>AR</i>	9/3/70

PROJECT AUTHORIZATION

1. PROJECT NUMBER 931-11-570-898	3. COUNTRY WORLDWIDE	4. AUTHORIZATION NUMBER TA 0092
2. PROJECT TITLE NEW YORK ACADEMY OF SCIENCES - THIRD INTERNATIONAL CONFERENCE ON PROSTAGLANDINS		5. AUTHORIZATION DATE <i>July 27, 1970</i>
7. LIFE OF PROJECT a. Number of Years of Funding: <u>1</u> Starting FY 19 <u>71</u> ; Terminal FY 19 <u>71</u>		6. PROP DATED <i>July 21, 1970</i>
		b. Estimated Duration of Physical Work After Last Year of Funding (in Months): <u>None</u>

FUNDING BY FISCAL YEAR (in U.S. \$ or \$ equivalent)	DOLLARS (000s)		P.L. 480 CCC + FREIGHT	LOCAL CURRENCY Exchange Rate: \$1 =			
	GRANT	LOAN		U.S. OWNED		HOST COUNTRY	
				GRANT	LOAN	JOINTLY PROGRAMMED	OTHER
Prior through Actual FY							
Operational FY 1971	\$60						
Budget FY							
B + 1 FY							
B + 2 FY							
B + 3 FY							
All Subsequent FY's							
TOTAL	\$60						

9. DESCRIBE SPECIAL FUNDING CONDITIONS OR RECOMMENDATIONS FOR IMPLEMENTATION, AND LIST KINDS AND QUANTITIES OF ANY P.L. 480 COMMODITIES

Items eligible for financing under this Authorization are limited exclusively to budget items 3 thru 7 for the conference as stated in the body of the PROP, and any funds not so utilized must be refunded to AID not later than June 30, 1971.

10. CONDITIONS OF APPROVAL OF PROJECT

No travel or per diem for employees of the USG or corporations established for profit may be paid from funds authorized under this Grant.

(Use continuation sheet if necessary)

11. Approved in substance for the life of the project as described in the PROP, subject to the conditions cited in Block 10 above, and the availability of funds. Detailed planning with cooperating country and drafting of implementation documents is authorized.

This authorization is contingent upon timely completion of the self-help and other conditions listed in the PROP or attached thereto.

This authorization will be reviewed at such time as the objectives, scope and nature of the project and/or the magnitudes and scheduling of any inputs or outputs deviate so significantly from the project as originally authorized as to warrant submission of a new or revised PROP.

A.I.D. APPROVAL	CLEARANCES	DATE
 SIGNATURE AA/TA, Mr. Joel Bernstein TITLE	JH Kean, TA/PM	7/27/70
	KS Levick, TA/PM	7/27/70
	RT Ravenholt, M.D., TA/PROP	7/27/70
	XXXXXX GC, ARichstein	7/29/70
7/29/70	DATE	